JP2006517581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517581A5 JP2006517581A5 JP2006502430A JP2006502430A JP2006517581A5 JP 2006517581 A5 JP2006517581 A5 JP 2006517581A5 JP 2006502430 A JP2006502430 A JP 2006502430A JP 2006502430 A JP2006502430 A JP 2006502430A JP 2006517581 A5 JP2006517581 A5 JP 2006517581A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- cdr
- antibody
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000002992 thymic effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 1
- 206010069754 Acquired gene mutation Diseases 0.000 claims 1
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 206010020564 Hyperadrenocorticism Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 101150070681 O12 gene Proteins 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229940030156 cell vaccine Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960003178 choline chloride Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 1
- 229940118537 p53 inhibitor Drugs 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000037439 somatic mutation Effects 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- KYLIMUJRJDIPPF-UHFFFAOYSA-N trisalicylate Chemical compound O=C1OC2=CC=CC=C2C(=O)OC2=CC=CC=C2C(=O)OC2=CC=CC=C12 KYLIMUJRJDIPPF-UHFFFAOYSA-N 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44735303P | 2003-02-13 | 2003-02-13 | |
| PCT/IB2004/000366 WO2004071529A2 (en) | 2003-02-13 | 2004-02-03 | Uses of anti-insulin-like growth factor i receptor antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517581A JP2006517581A (ja) | 2006-07-27 |
| JP2006517581A5 true JP2006517581A5 (https=) | 2007-03-15 |
Family
ID=32869626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502430A Pending JP2006517581A (ja) | 2003-02-13 | 2004-02-03 | 抗インスリン様増殖因子ｉ受容体抗体の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040202651A1 (https=) |
| EP (1) | EP1596885A2 (https=) |
| JP (1) | JP2006517581A (https=) |
| KR (2) | KR20070086866A (https=) |
| CN (2) | CN1753693A (https=) |
| AU (1) | AU2004212344B2 (https=) |
| BR (1) | BRPI0407485A (https=) |
| CA (1) | CA2514231A1 (https=) |
| IL (1) | IL169690A0 (https=) |
| MX (1) | MXPA05008617A (https=) |
| NZ (3) | NZ540971A (https=) |
| PL (1) | PL378812A1 (https=) |
| TW (2) | TW200501983A (https=) |
| WO (1) | WO2004071529A2 (https=) |
| ZA (1) | ZA200505215B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
| KR100467150B1 (ko) * | 2002-05-15 | 2005-01-24 | 삼성전자주식회사 | 부호분할다중접속 통신시스템의 단말기의 기지국 표시장치 및 방법 |
| EP1506286B1 (en) | 2002-05-24 | 2014-03-19 | Merck Sharp & Dohme Corp. | Neutralizing human anti-igfr antibody |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CA2524305C (en) * | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| DE602004029581D1 (de) | 2003-08-13 | 2010-11-25 | Pfizer Prod Inc | Modifizierte humane igf-1r antikörper |
| US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
| CN1886424A (zh) * | 2003-12-08 | 2006-12-27 | 伊缪诺金公司 | 抗igf－i受体抗体 |
| KR20080019733A (ko) | 2004-07-16 | 2008-03-04 | 화이자 프로덕츠 인코포레이티드 | 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료 |
| PT1828249E (pt) | 2004-12-03 | 2011-02-25 | Schering Corp | Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| JP4875064B2 (ja) * | 2005-04-15 | 2012-02-15 | シェーリング コーポレイション | 癌を処置または予防するための方法および組成物 |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| CA2612449A1 (en) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Receptor antagonists for treatment of metastatic bone cancer |
| AP2008004569A0 (en) | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| EP2104501B1 (en) | 2006-12-13 | 2014-03-12 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with igf1r inhibitors |
| EP2136839A4 (en) * | 2007-03-22 | 2010-04-07 | Imclone Llc | STABLE ANTIBODY FORMULATIONS |
| EP2559771A3 (en) | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| EP2167098B1 (en) * | 2007-06-11 | 2018-09-05 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| US20100204192A1 (en) * | 2007-06-11 | 2010-08-12 | University Of Sourthern California | Agents, compositions and methods for enhancing neurological function |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| ES2388017T3 (es) | 2007-12-21 | 2012-10-05 | Roche Glycart Ag | Ensayo de estabilidad de anticuerpos |
| NZ597692A (en) | 2008-12-12 | 2013-08-30 | Boehringer Ingelheim Int | Anti-IGF antibodies |
| JP2012513477A (ja) * | 2008-12-23 | 2012-06-14 | ソーク インスティチュート フォー バイオロジカル スタディーズ | 神経変性疾患の治療方法 |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
| SI2493922T1 (sl) | 2009-10-26 | 2017-06-30 | F. Hoffmann-La Roche Ag | Postopek za proizvodnjo glikoziliranega imunoglobulina |
| EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
| WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| RU2014105495A (ru) | 2011-07-19 | 2015-08-27 | Уилфред ДЖЕФФРИС | Способы диагностики и лечения болезни альцгеймера |
| EP2766497A1 (en) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| MX2017009759A (es) * | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| TWI705972B (zh) * | 2015-11-04 | 2020-10-01 | 臺北榮民總醫院 | 惡性病變的組合治療 |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| US20210332141A1 (en) | 2017-08-30 | 2021-10-28 | Amgen Inc. | Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use |
| MX2020003888A (es) * | 2017-10-18 | 2020-11-06 | Regenxbio Inc | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. |
| EP3737700A1 (en) | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| JP2024503933A (ja) | 2021-01-27 | 2024-01-29 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | Ｃｄ１６ａに対する単一ドメイン抗体およびその使用 |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE489915A (https=) * | 1948-07-01 | 1900-01-01 | ||
| US3235582A (en) * | 1962-09-07 | 1966-02-15 | Dow Chemical Co | Cyclohexylmethyl phenoxyacetate |
| US4086503A (en) * | 1976-06-21 | 1978-04-25 | Westinghouse Electric Corporation | Control circuit initiating conduction of an opto-isolator unit |
| US4202655A (en) * | 1977-06-10 | 1980-05-13 | Maloof Ralph P | Propeller fan blading and hub therefor |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| IL118626A0 (en) * | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibody |
| CA2321222A1 (fr) * | 1998-02-20 | 1999-08-26 | Commissariat A L'energie Atomique | Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications |
| US6251863B1 (en) * | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US6083936A (en) * | 1999-01-25 | 2000-07-04 | Sri International | Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use |
| ME00502B (me) * | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| MX370489B (es) * | 2004-01-09 | 2019-12-16 | Pfizer | Anticuerpos contra madcam. |
-
2004
- 2004-02-03 PL PL378812A patent/PL378812A1/pl unknown
- 2004-02-03 AU AU2004212344A patent/AU2004212344B2/en not_active Ceased
- 2004-02-03 BR BRPI0407485-8A patent/BRPI0407485A/pt not_active IP Right Cessation
- 2004-02-03 NZ NZ540971A patent/NZ540971A/en not_active IP Right Cessation
- 2004-02-03 WO PCT/IB2004/000366 patent/WO2004071529A2/en not_active Ceased
- 2004-02-03 CN CNA2004800041909A patent/CN1753693A/zh active Pending
- 2004-02-03 KR KR1020077015095A patent/KR20070086866A/ko not_active Ceased
- 2004-02-03 EP EP04707604A patent/EP1596885A2/en not_active Withdrawn
- 2004-02-03 JP JP2006502430A patent/JP2006517581A/ja active Pending
- 2004-02-03 CA CA002514231A patent/CA2514231A1/en not_active Abandoned
- 2004-02-03 NZ NZ582210A patent/NZ582210A/en not_active IP Right Cessation
- 2004-02-03 KR KR1020057014978A patent/KR20050109489A/ko not_active Ceased
- 2004-02-03 CN CNA2007101497312A patent/CN101164616A/zh active Pending
- 2004-02-03 MX MXPA05008617A patent/MXPA05008617A/es active IP Right Grant
- 2004-02-03 NZ NZ563207A patent/NZ563207A/en not_active IP Right Cessation
- 2004-02-10 US US10/775,444 patent/US20040202651A1/en not_active Abandoned
- 2004-02-12 TW TW093103332A patent/TW200501983A/zh unknown
- 2004-02-12 TW TW096121834A patent/TW200806318A/zh unknown
-
2005
- 2005-06-28 ZA ZA200505215A patent/ZA200505215B/en unknown
- 2005-07-14 IL IL169690A patent/IL169690A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517581A5 (https=) | ||
| JP7840836B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| TWI361696B (en) | A pharmaceutical composition comprising a human anti-tnf帢 antibody or antigen-binding portion thereof and use of a human anti- tnf帢 antibody or antigen-binding portion thereof | |
| JP2021530229A5 (https=) | ||
| JP7046804B2 (ja) | 改良された血清アルブミン結合剤 | |
| KR102580468B1 (ko) | Il-4r 억제제를 투여함으로써 알레르기 치료 및 알레르겐 특이적 면역요법을 강화시키는 방법 | |
| JP2022543387A5 (https=) | ||
| JP2008516970A5 (https=) | ||
| JP2021535733A5 (https=) | ||
| JP2006517581A (ja) | 抗インスリン様増殖因子ｉ受容体抗体の使用 | |
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| KR20170044739A (ko) | 안정한 항-ｉｌ-4ｒ-알파 항체 제형 | |
| TW200808821A (en) | Antibody purification | |
| JP2014158480A5 (https=) | ||
| SK288509B6 (sk) | Anti-TNFalfa protilátky na použitie pri liečení | |
| JP2018502060A5 (https=) | ||
| AU2016205852B2 (en) | Dosage regimen for MAdCAM antagonists | |
| TW201525004A (zh) | 結合前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之人類抗原結合蛋白 | |
| JP2021527063A5 (https=) | ||
| JP2015509097A5 (https=) | ||
| JP2023505492A5 (https=) | ||
| JPWO2020059847A5 (https=) | ||
| KR20200026789A (ko) | 시누클레인병증을 치료하기 위한 조성물 및 방법 | |
| JP2021520393A5 (https=) | ||
| JP2022540918A5 (https=) |